Buy OSI Pharmaceuticals (OSIP) on Weakness -Piper Jaffray
More News related to OSIP
- OSI Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009
- OSI Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference on Tuesday, November 3, 2009
- OSI Pharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
- Galleon Shuttered On Insider Trading Charges
- Trading Radar for 10/21: Boeing (BA), eBay (EBAY), Wells Fargo (WFC), US Bancorp (USB), Eli Lilly (ELY), St. Jude Medical (STJ) Report
More News related to Analyst Comments
- Credit Suisse Hikes Target on Vale (VALE) to $34; Sees 91% Jump in Profits Next Year
- S&P Raises Red Hat's (RHT) Corporate Credit Rating to 'BB+'
- S&P Places Sprint Nextel (S) Credit Rating On CreditWatch Negative
- Palm (PALM) Shares Rallying as Analysts Gaining Confidence
- Barclays Maintains an 'Equalweight' on Express Scripts (ESRX), Raises PT
Piper Jaffray reiterates its Buy rating and $50 price target on OSI Pharmaceuticals (Nasdaq: OSIP).
The firm mentions that OSI has a hearing scheduled next week in regards to license issues for Tarceva and Piper Jaffray believes that the license is unlikely to be granted. With the stock down almost 6% today, and about 23% year-to-date, Piper Jaffray said it would be a buyer of the OSI stock on current weakness.
OSI Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of oncology, diabetes, and obesity in the United States.
Related Categories
Analyst CommentsStocks Mentioned
+0.49Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
